NDAINJECTION, ORAL, RECTALSOLUTION
Approved
Oct 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
OMNIPAQUE 240 (iohexol) by GE HealthCare is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 1995.
Drug data last refreshed 12m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMNIPAQUE 240 is an iohexol-based radiographic contrast agent administered via injection, oral, or rectal routes to enhance X-ray imaging visibility. It works through X-ray contrast activity, allowing radiologists to visualize internal structures during diagnostic imaging procedures. The product is used across multiple imaging modalities including angiography, urography, and CT scanning.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), teams are likely focused on defending market share and managing transition to generic iohexol formulations.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Clinical Trials (4)
Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection
Started Apr 2019
24 enrolled
Contrast-induced NephropathyCoronary Angiography
A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants
Started Aug 2016
40 enrolled
Healthy
Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles
Started Feb 2013
84 enrolled
Colorectal Neoplasms
A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
Started Oct 2010
38 enrolled
Infections, Human Immunodeficiency Virus and Tuberculosis
Worked on OMNIPAQUE 240 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.